Verseon Corporation (VSN LN)

Verseon Corporation, a pharmaceutical company, designs and develops novel therapeutics for various diseases in the United States. It conducts drug discovery programs in the areas of anticoagulation, diabetic macular edema, and oncology. The company is involved in developing oral antico-agulants for various cardiovascular indications with novel pharmacology; potent kallikrein inhibitors for the treatment of diabetic macular edema delivered through topical eye drops; and novel angiogenesis inhibitors for the treatment of solid organ tumors. Verseon Corporation was founded in 2002 and is headquartered in Fremont, California.